Shares of medical device firm Nevro (NVRO) have lost 46% of their value since my February 2017 article stated that this medtech runner had further upside. The stock is in the red by 39% since my January 2018 article stated a rebound was likely in the year ahead.
With the chart showing signs of a rebound taking place and the large market opportunity targeted ($4 billion plus) contrasting sharply to the $1.25 billion market capitalization, I'm looking forward to revisiting despite my poor track record on this one.
Chart
Figure 1: NVRO daily advanced chart